BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29850358)

  • 1. Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome.
    Gorodetskiy VR; Salugina SO; Fedorov ES
    Case Rep Rheumatol; 2018; 2018():5416907. PubMed ID: 29850358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of Schnitzler's syndrome without monoclonal gammopathy successfully treated with canakinumab.
    Fujita Y; Asano T; Sakai A; Norikawa N; Yamamoto T; Matsumoto H; Sato S; Temmoku J; Yashiro-Furuya M; Matsuoka N; Watanabe H; Migita K
    BMC Musculoskelet Disord; 2021 Mar; 22(1):257. PubMed ID: 33685423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.
    de Koning HD; Schalkwijk J; van der Ven-Jongekrijg J; Stoffels M; van der Meer JW; Simon A
    Ann Rheum Dis; 2013 Oct; 72(10):1634-8. PubMed ID: 23087179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of interleukin-1 blockade in Schnitzler's syndrome without detectable monoclonal gammopathy: a case-based review.
    Bixio R; Rossini M; Giollo A
    Clin Rheumatol; 2021 Jul; 40(7):2973-2977. PubMed ID: 33175311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schnitzler's Syndrome-Diagnostic Experience, Approaches to Therapy, and Patient Management according to a Multicenter Russian Cohort.
    Salugina SO; Torgashina AV; Borzova EY; Rameev VV; Gorodetsky VR; Fedorov ES; Muravyova NV
    Dokl Biochem Biophys; 2024 Jun; ():. PubMed ID: 38861148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of interleukin-1 beta in the pathophysiology of Schnitzler's syndrome.
    de Koning HD; Schalkwijk J; Stoffels M; Jongekrijg J; Jacobs JF; Verwiel E; Koenen HJ; Preijers F; Holzinger D; Joosten I; van der Meer JW; Simon A
    Arthritis Res Ther; 2015 Jul; 17(1):187. PubMed ID: 26198339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mast-cell interleukin-1β, neutrophil interleukin-17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler's syndrome.
    de Koning HD; van Vlijmen-Willems IM; Rodijk-Olthuis D; van der Meer JW; Zeeuwen PL; Simon A; Schalkwijk J
    Br J Dermatol; 2015 Aug; 173(2):448-56. PubMed ID: 25904179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab.
    Salcedo-Mingoarranz AL; Dorado-Fernández M; García-Martínez S; Collado-Ramos P; Silvestre-Torner N
    J Dermatolog Treat; 2023 Dec; 34(1):2242705. PubMed ID: 37551725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Case of Schnitzler's Syndrome without Monoclonal Gammopathy-Associated Chronic Urticaria Treated with Anakinra.
    Ahn MJ; Yu JE; Jeong J; Sim DW; Koh YI
    Yonsei Med J; 2018 Jan; 59(1):154-157. PubMed ID: 29214791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schnitzler's Syndrome: A Diagnostic Consideration in Evaluating the Constellation of Monoclonal Gammopathy and Chronic Urticaria.
    Mamadgi J; Babar L; Bhagavatula R; Sadashiv S; Dantey K; Apostolova M
    J Hematol; 2021 Jun; 10(3):143-146. PubMed ID: 34267853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different Therapeutic Paths (Colchicine vs. Anakinra) in Two Patients With Schnitzler's Syndrome.
    Barešić M; Mitrović J; Morović Vergles J; Anić B
    Arch Rheumatol; 2016 Dec; 31(4):377-380. PubMed ID: 30375570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schnitzler's syndrome: diagnosis, treatment, and follow-up.
    Simon A; Asli B; Braun-Falco M; De Koning H; Fermand JP; Grattan C; Krause K; Lachmann H; Lenormand C; Martinez-Taboada V; Maurer M; Peters M; Rizzi R; Rongioletti F; Ruzicka T; Schnitzler L; Schubert B; Sibilia J; Lipsker D
    Allergy; 2013; 68(5):562-8. PubMed ID: 23480774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schnitzler's syndrome: lessons from 281 cases.
    de Koning HD
    Clin Transl Allergy; 2014; 4():41. PubMed ID: 25905009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin and Systemic Inflammation in Schnitzler's Syndrome Are Associated With Neutrophil Extracellular Trap Formation.
    Bonnekoh H; Scheffel J; Wu J; Hoffmann S; Maurer M; Krause K
    Front Immunol; 2019; 10():546. PubMed ID: 30967871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schnitzler's syndrome - a novel hypothesis of a shared pathophysiologic mechanism with Waldenström's disease.
    van Leersum FS; Potjewijd J; van Geel M; Steijlen PM; Vreeburg M
    Orphanet J Rare Dis; 2019 Jun; 14(1):151. PubMed ID: 31228950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome.
    de Koning HD; Bodar EJ; Simon A; van der Hilst JC; Netea MG; van der Meer JW
    Ann Rheum Dis; 2006 Apr; 65(4):542-4. PubMed ID: 16096327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retention rate of IL-1 inhibitors in Schnitzler's syndrome.
    Crisafulli F; Vitale A; Airò P; Grigis M; Gaggiano C; Dagna L; Cavalli G; Cimaz R; Viapiana O; Iannone F; Lopalco G; Bortolotti R; Abdel Jaber M; Montecucco C; Monti S; Balduzzi S; Emmi G; Mattioli I; Franceschini F; Cantarini L; Frassi M
    Clin Exp Rheumatol; 2022 Nov; 40(11):2011-2017. PubMed ID: 35084307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study.
    Néel A; Henry B; Barbarot S; Masseau A; Perrin F; Bernier C; Kyndt X; Puechal X; Weiller PJ; Decaux O; Ninet J; Hot A; Aouba A; Astudillo L; Berthelot JM; Bonnet F; Brisseau JM; Cador B; Closs-Prophette F; Dejoie T; de Korwin JD; Dhote R; Fior R; Grosbois B; Hachulla E; Hatron PY; Jardel H; Launay D; Lorleac'h A; Pottier P; Moulis G; Serratrice J; Smail A; Hamidou M
    Autoimmun Rev; 2014 Oct; 13(10):1035-41. PubMed ID: 25220180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Chinese case series of Schnitzler syndrome and complete remission in one tocilizumab-treated patient.
    Yan R; Cao W; Liu X; Li F; Shen M
    Clin Rheumatol; 2020 Dec; 39(12):3847-3852. PubMed ID: 32519052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urticarial pathology in Schnitzler's (hyper-IgM) syndrome.
    de Castro FR; Masouyé I; Winkelmann RK; Saurat JH
    Dermatology; 1996; 193(2):94-9. PubMed ID: 8884142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.